Boston Scientific Corporation (BSX) earnings on July 29, 2026

Before the market opens Q2 2026

More Boston Scientific Corporation earnings

Prior outlook: Optimistic Outcome: Partial

The stock seesawed dramatically, swinging from a 9% gain to a 10% loss before ending nearly unchanged, erasing earlier gains.

BSX price around the earnings

46.04

Change: -0.0%

2026-07-29, 20:00 UTC

Start of the measured window End of the measured window
41.73 44.49 47.25 50.01 46.06
Price series around the eventClosing price per minute from before the event to the end of the measured window.
July 29, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Partial

Thesis published
Results released

Strong analyst conviction (+57% price target above current), restructuring catalyst ($500M savings), strong recent beat history; catalysts largely priced in.

Context analyzed before publication

Trend
Strong improvement 2.1→88.0 over 7 days; restructuring and patent catalysts driving trend strength; elevated sell-the-news risk

Analysts

Evidence

Analyst consensus
Strong buy
Consensus average (1-5)
1.5
Analysts covering the stock
29
Average price target
72.31
Lowest price target
55
Highest price target
106
Upside to price target
57%
Quarterly earnings growth
99%
Revenue growth
11.6%
Forward EPS
3.71
Trailing EPS
2.42
Analyst moves in the last 60 days
10
  • Strong buy: 7
  • Buy: 20
  • Hold: 4
  • Sell: 0
  • Strong sell: 0
Strong buy
7
Buy
20
Hold
4
Sell
0
Strong sell
0
  • July 27, 2026 · Oppenheimer: Maintains rating (Outperform → Outperform)
  • July 16, 2026 · Truist Securities: Maintains rating (Buy → Buy)
  • July 15, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
  • July 13, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
  • July 8, 2026 · Needham: Maintains rating (Buy → Buy)
  • July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
  • June 25, 2026 · Stifel: Maintains rating (Buy → Buy)
  • June 24, 2026 · Jefferies: Maintains rating (Buy → Buy)
  • June 16, 2026 · BTIG: Reiterates rating (Buy → Buy)
  • June 4, 2026 · Truist Securities: Maintains rating (Buy → Buy)

News and sentiment

Evidence

Sentiment
Sentiment
Constructive
Mention volume
Low
Normalized volume
33%
News
Sources (8)

Technicals

Evidence

Price when the context was analyzed
46.12
Average true range (ATR)
3.1%
Distance to 52-week high
-57.9%
14-day change (14d)
+8.2%
30-day change (32d)
+4.5%
30-day relative strength
+2.9%
SPY change (32d)
+1.6%
Nearest support
45.81
Distance to nearest support
0.7%
Nearest resistance
46.24
Distance to nearest resistance
0.3%
Volume accumulation ratio (14d / 46d)
0.83
  • Mid: 45.81 (0.7% away, 0.22 ATR, 10 touches)
  • Mid: 45.49 (1.4% away, 0.45 ATR, 27 touches)
  • Major: 45.18 (2.1% away, 0.67 ATR, 30 touches)
  • Minor: 46.24 (0.3% away, 0.08 ATR, 8 touches)
  • Mid: 46.68 (1.2% away, 0.39 ATR, 4 touches)
  • Minor: 46.91 (1.7% away, 0.56 ATR, 2 touches)

Trends

Evidence

Average earnings surprise
+3.1%
  • April 22, 2026: actual EPS 0.8 vs estimate 0.79 (surprise +1.6%)
  • February 4, 2026: actual EPS 0.8 vs estimate 0.78 (surprise +2.4%)
  • October 22, 2025: actual EPS 0.75 vs estimate 0.71 (surprise +5.1%)
  • July 23, 2025: actual EPS 0.75 vs estimate 0.73 (surprise +3.4%)

Expected move

Implied move
+7.2%
Source
Options chain

Reactions over its last 20 earnings

Median move
2.9%
75th percentile move
4.5%
90th percentile move
6.4%
Up / down moves
13 / 7
Average up move
+3.6%
Average down move
-3.7%

Monitoring and close

What Boston Scientific Corporation reported

Status
Finished
Actual EPS0.86
EPS estimate0.83
EPS surprise+3.6%
Revenue$5,442 million
Revenue estimate$5,361 million
Revenue surprise+1.5%

Boston Scientific reports strong Q2 with revenue and earnings above expectations, but cuts full-year outlook due to slowing WATCHMAN demand.

Sources (27)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, the figures confirm the optimistic scenario. In the 1266 past cases with a similar move, the close held that direction 86% of the time.

How the stock reacted

Outcome
Partial
Consolidated
-0.0%
Max favorable move (MFE)
9.2%
Max adverse move (MAE)
9.9%